electroCore, Inc. (ECOR)
Market Cap | 34.67M |
Revenue (ttm) | 26.46M |
Net Income (ttm) | -12.24M |
Shares Out | 7.19M |
EPS (ttm) | -1.56 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 345,494 |
Open | 4.790 |
Previous Close | 4.650 |
Day's Range | 4.502 - 4.995 |
52-Week Range | 5.020 - 19.490 |
Beta | 0.92 |
Analysts | Strong Buy |
Price Target | 25.50 (+429.05%) |
Earnings Date | May 7, 2025 |
About ECOR
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electron... [Read more]
Financial Performance
In 2024, electroCore's revenue was $25.18 million, an increase of 57.09% compared to the previous year's $16.03 million. Losses were -$11.89 million, -36.89% less than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price forecast is $25.5, which is an increase of 429.05% from the latest price.
News

electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Goldberger - Chief Executive Officer and Director Joshua Lev - Chief Financial Officer...

electroCore Announces First Quarter 2025 Financial Results
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of ap...

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies
Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets Addition of Quell® Platform Broadens electroCore's Bio...

electroCore's Truvaga™ Now Works with the Apple Health app
ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, T...

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025
ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the ...

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries
ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025...

electroCore to Participate at the Planet MicroCap Showcase
ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in...

electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times
ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one o...

electroCore to Participate at the Needham Virtual Healthcare Conference
ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at...

electroCore Extends VA Contract for Five Years
ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new...

electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Par...

electroCore Announces Full Year 2024 Financial Results
Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM in the United States Department of Veteran A...

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025
ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial r...

electroCore to Participate at Upcoming Investor Conferences
Management to Attend the 37th Annual Roth Conference and the LSI USA '25 Management to Attend the 37th Annual Roth Conference and the LSI USA '25

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal
ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomed...

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual...

electroCore: An Opportunity In Medical And Wellness Device Innovation
electroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headac...

electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM
electroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifyin...

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in ...

electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call...

electroCore Announces Third Quarter 2024 Financial Results
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales

ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness prod...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freebur...

electroCore to Participate at LD Micro Main Event VXII
Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will parti...